PIPE 307
Alternative Names: JNJ 5120; PIPE-307Latest Information Update: 28 Apr 2025
At a glance
- Originator Pipeline Therapeutics
- Developer Contineum Therapeutics; Janssen Pharmaceutica
- Class Antidepressants; Small molecules
- Mechanism of Action Muscarinic M1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders; Multiple sclerosis
Most Recent Events
- 28 Apr 2025 Phase-II clinical trials in Depressive disorders (PO) (Janssen Research & Development pipeline, April 2025)
- 08 Jan 2025 Contineum Therapeutics completes enrolment in the phase-II VISTA trial for Multiple sclerosis in USA (NCT06083753),
- 28 Oct 2024 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in United Kingdom (PO, Tablet)